Skip to main content
User Image

Shaun Sabico

Associate Professor

Associate Professor and Deputy Director

Sciences
Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, KSU
publication
Journal Article
2026

Comparative effects of metformin and lifestyle therapy on bone metabolism markers: A 6-month pilot, open-label randomized-clinical trial

Background: The metabolic effects of Metformin (Met) and lifestyle modification in early type 2 diabetes mellitus (T2DM) management are well established, but their influence on bone remodeling remains uncertain in under-investigated populations, particularly during early treatment when weight loss and metabolic shifts may transiently affect skeletal turnover. This study examined the short- and mid-term effects of metformin, lifestyle intervention, and their combination on bone turnover markers (BTMs) in treatment-naïve Saudi adults with T2DM.

Methods: In this 6-month pilot, open-label multicenter randomized controlled trial, 114 treatment-naïve Saudi adults with newly diagnosed T2DM (90 males, 24 females; mean age ± SD 53.6 ± 8.4 years; mean BMI 30.3 ± 3.9 kg/m2; mean HbA1c 7.0 ± 0.6) were assigned to Met (1000 mg/day), lifestyle modification, or combined therapy (n = 38/group). Serum markers of bone resorption (C-terminal telopeptide of type I collagen [CTX], primary outcome) and bone formation (procollagen type I N-terminal propeptide [P1NP], osteocalcin), along with sclerostin (SOST), were measured at baseline, 3 months, and 6 months. Anthropometric, glycemic, lipid, renal, and hepatic parameters were assessed as secondary outcomes.

Results: After adjustment for baseline P1NP levels, only the lifestyle group demonstrated a significant reduction in CTX after 6 months (p < 0.05), while osteocalcin, SOST and P1NP showed no significant changes across all interventions. All interventions were associated with improvements in anthropometric and glycemic measures; most pronounced in the combined intervention group.

Conclusion: In treatment-naïve adults with T2DM, lifestyle intervention alone was associated with a significant reduction in CTX after 6 months, while metformin-based interventions showed no significant effects on bone turnover markers. These exploratory findings may suggest short-term modulation of bone turnover but should be interpreted cautiously given the pilot design.

Publisher Name
Aging Clinical and Experimental Research
more of publication
publications

Introduction: Healthful plant-based foods can improve youth nutrition and contribute to global targets such as Sustainable Development Goal (SDG) 2 on ending malnutrition, SDG3…

by Yearley S, Miller V, Cudhea F, Shi P, Sharib JR, Lara-Castor L, Essel K, Micha R, Zhang J, Mozaffarian D; Global Dietary Database
2026
Published in:
BMJ Global Health
publications

Background: The metabolic effects of Metformin (Met) and lifestyle modification in early type 2 diabetes mellitus (T2DM) management are well established, but their influence on…

by Almosfer M, Sabico S, Wani K, Khattak MNK, Almarashad IS, Veronese N, Al-Daghri NM
2026
Published in:
Aging Clinical and Experimental Research
publications

Background: Taxes on sugar-sweetened beverages can improve public health. We aimed to characterise the extent and types of sugar-sweetened beverage taxes implemented worldwide and…

by Loaeza LM, Lara-Castor L, Sharib JR, Cudhea F, Wang M, Li P, Mozaffarian D; Global Dietary Database collaborators
2026
Published in:
Lancet Global Health